<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03871790</url>
  </required_header>
  <id_info>
    <org_study_id>PICOP-GLOBAL-2019</org_study_id>
    <nct_id>NCT03871790</nct_id>
  </id_info>
  <brief_title>Peptide-based Immunization for Colon- and and Pancreas-carcinoma</brief_title>
  <acronym>PICOP-GLOBAL</acronym>
  <official_title>Peptide-based Immunization for Colon- and Pancreas-carcinoma (PICOP-GLOBAL): An International, Multicenter Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centogene AG Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centogene AG Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An international, multicenter study to identify tumor molecular particularities and
      neoepitopes among participants with colorectal and pancreatic tumors undergoing surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal and pancreatic cancers are among the most common causes of cancer-related death
      over the world. Standard of care treatment for colon and pancreas cancer is stage dependent
      and includes surgical, chemotherapeutic, and radiation therapy. However, the current
      statistics underlines an urgent need for improved treatment. Patient-individualized
      treatments and enhancement of the immune response via vaccination are among new therapeutic
      options.

      The enhancement of the immune response via vaccination is among new therapeutic options.
      Here, either cell-specific antigens, over-expressed tumor specific antigens or mutated
      tumor-specific antigens (neoepitopes) can be employed. Especially the latter possess the
      biggest potential for high specificity but presuppose an extensive characterization of the
      respective tumor. In order to identify a neoepitope-based vaccination approach for
      patient-individualized treatment options the molecular particularities of tumors have to be
      analysed.

      The aim of this study is to identify tumor molecular particularities and neoepitopes among
      patients with colorectal and pancreatic tumors undergoing surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of tumor specific mutations on the genomic level</measure>
    <time_frame>24 months</time_frame>
    <description>Identification of tumor specific mutations on the genomic level using whole exome sequencing and/or whole genome sequencing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of tumor specific mutations on transcriptional and/or translational level</measure>
    <time_frame>24 months</time_frame>
    <description>Direct comparison of tumor and non-tumor tissue to identify somatic mutations through RNA sequencing and proteomics analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of neo-antigens epitopes at protein level</measure>
    <time_frame>24 months</time_frame>
    <description>Identification of neo-antigens epitopes at protein level via mass spectrography</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colon Neoplasm</condition>
  <condition>Colon Adenocarcinoma</condition>
  <condition>Colon Cancer</condition>
  <condition>Colo-rectal Cancer</condition>
  <condition>Rectal Cancer</condition>
  <condition>Rectal Neoplasms</condition>
  <condition>Rectal Adenocarcinoma</condition>
  <condition>Rectal Tumors</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Pancreas Cancer</condition>
  <condition>Pancreatic Neoplasms</condition>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Participants with colorectal cancer</arm_group_label>
    <description>Participants with colorectal cancer ongoing surgery older than 18 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants with pancreatic cancer</arm_group_label>
    <description>Participants with pancreatic cancer ongoing surgery older than 18 years old.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood in EDTA tube, blood in Cell-free DNA tube (Streck tube), and blood in Heparin tube
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with colorectal or pancreas carcinoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent is obtained from the participant

          -  Patients with pancreas or colorectal carcinoma undergoing surgery

          -  The participant is older than 18 years old

        Exclusion Criteria:

          -  Inability to provide informed consent

          -  The patient is not suffering from pancreas or colo-rectal carcinoma

          -  Patient has a condition contradicting surgery

          -  The participant is younger than 18 years old

          -  Previously enrolled in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Peter Bauer, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centogene AG Rostock</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Volha Skrahina, PhD</last_name>
    <phone>+49 (0)38180113594</phone>
    <email>Volha.Skrahina@centogene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susann Krake, PhD</last_name>
    <phone>+49 (0)38180113530</phone>
    <email>Susann.Krake@centogene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Teaching Hospital UOL Cancer Center</name>
      <address>
        <city>Lahore</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Arshad Cheema, MD</last_name>
      <phone>+92 (0)3008017150</phone>
      <email>cancersurgerypk@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Muhammad Arshad Cheema, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <reference>
    <citation>Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson BJ, Iseli C, Michel A, Le Bitoux MA, Guillaume P, Schmidt J, Bianchi V, Dangaj D, Fenwick C, Derr√© L, Xenarios I, Michielin O, Romero P, Monos DS, Zoete V, Gfeller D, Kandalaft LE, Coukos G, Harari A. Sensitive and frequent identification of high avidity neo-epitope specific CD8 (+) T cells in immunotherapy-naive ovarian cancer. Nat Commun. 2018 Mar 15;9(1):1092. doi: 10.1038/s41467-018-03301-0.</citation>
    <PMID>29545564</PMID>
  </reference>
  <reference>
    <citation>Bousquet G, Janin A. Patient-Derived Xenograft: An Adjuvant Technology for the Treatment of Metastatic Disease. Pathobiology. 2016;83(4):170-6. doi: 10.1159/000444533. Epub 2016 Mar 25. Review.</citation>
    <PMID>27010922</PMID>
  </reference>
  <reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.</citation>
    <PMID>30207593</PMID>
  </reference>
  <reference>
    <citation>Cho YT, Su H, Wu WJ, Wu DC, Hou MF, Kuo CH, Shiea J. Biomarker Characterization by MALDI-TOF/MS. Adv Clin Chem. 2015;69:209-54. doi: 10.1016/bs.acc.2015.01.001. Epub 2015 Feb 17. Review.</citation>
    <PMID>25934363</PMID>
  </reference>
  <reference>
    <citation>Dangles-Marie V, Pocard M, Richon S, Weiswald LB, Assayag F, Saulnier P, Judde JG, Janneau JL, Auger N, Validire P, Dutrillaux B, Praz F, Bellet D, Poupon MF. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res. 2007 Jan 1;67(1):398-407.</citation>
    <PMID>17210723</PMID>
  </reference>
  <reference>
    <citation>Maule M, Merletti F. Cancer transition and priorities for cancer control. Lancet Oncol. 2012 Aug;13(8):745-6. doi: 10.1016/S1470-2045(12)70268-1.</citation>
    <PMID>22846827</PMID>
  </reference>
  <reference>
    <citation>Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, Marass F, Humphray S, Hadfield J, Bentley D, Chin TM, Brenton JD, Caldas C, Rosenfeld N. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013 May 2;497(7447):108-12. doi: 10.1038/nature12065. Epub 2013 Apr 7.</citation>
    <PMID>23563269</PMID>
  </reference>
  <reference>
    <citation>Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 2009 Nov 20;27(33):5660-9. doi: 10.1200/JCO.2009.21.9022. Epub 2009 Oct 26. Review.</citation>
    <PMID>19858397</PMID>
  </reference>
  <reference>
    <citation>Pompili L, Porru M, Caruso C, Biroccio A, Leonetti C. Patient-derived xenografts: a relevant preclinical model for drug development. J Exp Clin Cancer Res. 2016 Dec 5;35(1):189. Review.</citation>
    <PMID>27919280</PMID>
  </reference>
  <reference>
    <citation>Rammensee HG, Singh-Jasuja H. HLA ligandome tumor antigen discovery for personalized vaccine approach. Expert Rev Vaccines. 2013 Oct;12(10):1211-7. doi: 10.1586/14760584.2013.836911. Epub 2013 Oct 4. Review.</citation>
    <PMID>24090147</PMID>
  </reference>
  <reference>
    <citation>Shaw JA, Stebbing J. Circulating free DNA in the management of breast cancer. Ann Transl Med. 2014 Jan;2(1):3. doi: 10.3978/j.issn.2305-5839.2013.06.06.</citation>
    <PMID>25332979</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 8, 2019</study_first_submitted>
  <study_first_submitted_qc>March 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoepitopes</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Tumor-specific antigens</keyword>
  <keyword>Personalized medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

